Literature DB >> 22820353

[Immunohistochemical comparison between GCDFP-15 and estrogen and progesterone receptors in the diagnosis of metastatic carcinoma of the breast].

Jaime Villarroel Salinas1, Carlos Ortiz Hidalgo, Danny Soria Céspedes.   

Abstract

BACKGROUND: In the workup of tumors of unknown primary origin in women, a frequent consideration is breast carcinoma, because it is common and may initially present as metastasis.
OBJECTIVE: Describe and compare the immunohistochemical profile of hormonal receptors (estrogen receptor and progesterone receptor) and GCDFP-15 in lymph node metastatic breast carcinoma according the histological grade.
METHODS: Retrospective study analyzing 30 patients with identified primary breast cancer and lymph node metastasis. The cases were divided in three groups: grade I (well differentiated), grade II (moderately differentiated) and grade III (poorly differentiated). We used three antibodies (estrogen receptor, progesterone receptor and GCDFP-15) in the lymph node and compare the expression according the histological grade.
RESULTS: In metastatic lymph node from grade I breast carcinomas the hormone receptors were 100% positive and GCDFP-15 was 80% positive. In grade II, estrogen receptor and progesterone receptor were positive in 90 and 40% respectively, and GCDFP-15 was positive in 80%. In grade III, estrogen receptor and progesterone receptor were positive in 30 and 50% respectively, and GCDFP-15 in 60%.
CONCLUSIONS: The immunohistochemical expression of hormonal receptors and GCDFP-15 in metastatic breast carcinoma is related to histological grade in the breast.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22820353

Source DB:  PubMed          Journal:  Gac Med Mex        ISSN: 0016-3813            Impact factor:   0.302


  1 in total

Review 1.  Gastric and adrenal metastasis from breast cancer: Case report and review of literature.

Authors:  Tiantian Tang; Lina Zhang; Chunxiao Li; Tao Zhou
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.